Sort by

Send to

Choose Destination

Links from PubMed

Items: 18


Resveratrol augments ER stress and the cytotoxic effects of glycolytic inhibition in neuroblastoma by downregulating Akt in a mechanism independent of SIRT1.

Graham RM, Hernandez F, Puerta N, De Angulo G, Webster KA, Vanni S.

Exp Mol Med. 2016 Feb 19;48:e210. doi: 10.1038/emm.2015.116.


2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3β Activation.

Kovács K, Decatur C, Toro M, Pham DG, Liu H, Jing Y, Murray TG, Lampidis TJ, Merchan JR.

Mol Cancer Ther. 2016 Feb;15(2):264-75. doi: 10.1158/1535-7163.MCT-14-0315.


Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice.

Huang CC, Wang SY, Lin LL, Wang PW, Chen TY, Hsu WM, Lin TK, Liou CW, Chuang JH.

Dis Model Mech. 2015 Oct 1;8(10):1247-54. doi: 10.1242/dmm.021667.


Endothelial cell metabolism in normal and diseased vasculature.

Eelen G, de Zeeuw P, Simons M, Carmeliet P.

Circ Res. 2015 Mar 27;116(7):1231-44. doi: 10.1161/CIRCRESAHA.116.302855. Review.


Endothelial cell metabolism: parallels and divergences with cancer cell metabolism.

Verdegem D, Moens S, Stapor P, Carmeliet P.

Cancer Metab. 2014 Sep 15;2:19. doi: 10.1186/2049-3002-2-19. Review.


Modulation of endothelial cell migration by ER stress and insulin resistance: a role during maternal obesity?

Sáez PJ, Villalobos-Labra R, Westermeier F, Sobrevia L, Farías-Jofré M.

Front Pharmacol. 2014 Aug 19;5:189. doi: 10.3389/fphar.2014.00189. Review.


Endothelial PFKFB3 plays a critical role in angiogenesis.

Xu Y, An X, Guo X, Habtetsion TG, Wang Y, Xu X, Kandala S, Li Q, Li H, Zhang C, Caldwell RB, Fulton DJ, Su Y, Hoda MN, Zhou G, Wu C, Huo Y.

Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1231-9. doi: 10.1161/ATVBAHA.113.303041.


Deoxyglucose prevents neurodegeneration in culture by eliminating microglia.

Vilalta A, Brown GC.

J Neuroinflammation. 2014 Mar 26;11:58. doi: 10.1186/1742-2094-11-58.


In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.

Jing Y, Zaias J, Duncan R, Russell SJ, Merchan JR.

Gene Ther. 2014 Mar;21(3):289-97. doi: 10.1038/gt.2013.84.


Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose.

Philips KB, Kurtoglu M, Leung HJ, Liu H, Gao N, Lehrman MA, Murray TG, Lampidis TJ.

Cancer Chemother Pharmacol. 2014 Feb;73(2):349-61. doi: 10.1007/s00280-013-2358-8.


Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck.

Kurisetty VV, Heiber J, Myers R, Pereira GS, Goodwin JW, Federspiel MJ, Russell SJ, Peng KW, Barber G, Merchan JR.

Head Neck. 2014 Nov;36(11):1619-27. doi: 10.1002/hed.23502.


Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response.

Bénéteau M, Zunino B, Jacquin MA, Meynet O, Chiche J, Pradelli LA, Marchetti S, Cornille A, Carles M, Ricci JE.

Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):20071-6. doi: 10.1073/pnas.1206360109.


Activation of the unfolded protein response by 2-deoxy-D-glucose inhibits Kaposi's sarcoma-associated herpesvirus replication and gene expression.

Leung HJ, Duran EM, Kurtoglu M, Andreansky S, Lampidis TJ, Mesri EA.

Antimicrob Agents Chemother. 2012 Nov;56(11):5794-803. doi: 10.1128/AAC.01126-12.


Role of plasminogen activator inhibitor-1 in urokinase's paradoxical in vivo tumor suppressing or promoting effects.

Jing Y, Kovacs K, Kurisetty V, Jiang Z, Tsinoremas N, Merchan JR.

Mol Cancer Res. 2012 Oct;10(10):1271-81. doi: 10.1158/1541-7786.MCR-12-0145.


Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors.

Piña Y, Houston SK, Murray TG, Koru-Sengul T, Decatur C, Scott WK, Nathanson L, Clarke J, Lampidis TJ.

Clin Ophthalmol. 2012;6:817-30. doi: 10.2147/OPTH.S29688.


Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors.

Piña Y, Decatur C, Murray TG, Houston SK, Lopez-Cavalcante M, Hernandez E, Celdran M, Shah N, Feuer W, Lampidis T.

Invest Ophthalmol Vis Sci. 2012 Feb;53(2):996-1002. doi: 10.1167/iovs.11-8265.


A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events.

Valapala M, Thamake SI, Vishwanatha JK.

J Cell Sci. 2011 May 1;124(Pt 9):1453-64. doi: 10.1242/jcs.079236.


Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors.

Houston SK, Piña Y, Murray TG, Boutrid H, Cebulla C, Schefler AC, Shi W, Celdran M, Feuer W, Merchan J, Lampidis TJ.

Clin Ophthalmol. 2011 Jan 27;5:129-37. doi: 10.2147/OPTH.S15179.

Items per page

Supplemental Content

Support Center